Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | IGF1R | P08069 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24309830 | 0.88 | IGF1R (0.32) | IGF1R | |
| SCHEMBL24309899 | 0.86 | NPC1 (0.33) | CYP1A2CYP2C19IGF1R | |
| SCHEMBL24309901 | 0.86 | IGF1R (0.33) | IGF1R | |
| SCHEMBL24309917 | 0.86 | MAPK14 (0.33) | IGF1R | |
| SCHEMBL24310179 | 0.86 | IGF1R (0.31) | IGF1R | |
| SCHEMBL24310590 | 0.85 | IGF1R (0.31) | IGF1R | |
| SCHEMBL24309404 | 0.85 | CNR1 (0.35) | LMNACYP1A2CYP2C19ADORA1ADORA2B | |
| SCHEMBL24310383 | 0.84 | KDM5A (0.32) | IGF1R | |
| SCHEMBL24309378 | 0.84 | IGF1R (0.30) | IGF1R | |
| SCHEMBL24309438 | 0.83 | GABRG2 (0.30) | IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |